MA49599A1 - Anticorps spécifiques à cd47 et pd-l1 - Google Patents

Anticorps spécifiques à cd47 et pd-l1

Info

Publication number
MA49599A1
MA49599A1 MA49599A MA49599A MA49599A1 MA 49599 A1 MA49599 A1 MA 49599A1 MA 49599 A MA49599 A MA 49599A MA 49599 A MA49599 A MA 49599A MA 49599 A1 MA49599 A1 MA 49599A1
Authority
MA
Morocco
Prior art keywords
antibodies
relates
antibodies specific
antibody
antigen binding
Prior art date
Application number
MA49599A
Other languages
English (en)
Other versions
MA49599B1 (fr
Inventor
Timofey Aleksandrovich Nemankin
Kirill Vladimirovich Solovyev
Andrei Borisovich Ulitin
Valery Vladimirovich Solovyev
Dmitry Valentinovich Morozov
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of MA49599A1 publication Critical patent/MA49599A1/fr
Publication of MA49599B1 publication Critical patent/MA49599B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne le domaine de la biotechnologie et notamment le domaine des anticorps ou leurs fragments de liaison d'antigènes ainsi que leur utilisation. Elle concerne plus particulièrement des anticorps qui se lient spécifiquement à cd47 et pd-l1. L'invention concerne également un acide nucléique codant pour cet anticorps ou son fragment de liaison d'antigènes, un vecteur d'expression, un procédé de production d'anticorps et l'utilisation de ces anticorps et composition dans la thérapie du cancer.
MA49599A 2017-10-03 2018-10-03 Anticorps spécifiques à cd47 et pd-l1 MA49599B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EA201791961A EA039662B1 (ru) 2017-10-03 2017-10-03 Антитела, специфичные к cd47 и pd-l1
PCT/EA2018/050001 WO2019068302A1 (fr) 2017-10-03 2018-10-03 Anticorps spécifiques à cd47 et pd-l1

Publications (2)

Publication Number Publication Date
MA49599A1 true MA49599A1 (fr) 2021-01-29
MA49599B1 MA49599B1 (fr) 2023-05-31

Family

ID=65994976

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49599A MA49599B1 (fr) 2017-10-03 2018-10-03 Anticorps spécifiques à cd47 et pd-l1

Country Status (21)

Country Link
US (1) US11840567B2 (fr)
EP (1) EP3693390A4 (fr)
JP (2) JP2020535839A (fr)
KR (1) KR102937863B1 (fr)
CN (1) CN111801352B (fr)
AR (1) AR113342A1 (fr)
AU (1) AU2018345458B2 (fr)
BR (1) BR112020006706A2 (fr)
CA (1) CA3078413A1 (fr)
CL (1) CL2020000919A1 (fr)
CO (1) CO2020004199A2 (fr)
EA (1) EA039662B1 (fr)
EC (1) ECSP20024555A (fr)
JO (1) JOP20200078B1 (fr)
MA (1) MA49599B1 (fr)
MX (1) MX2020004027A (fr)
PE (1) PE20210460A1 (fr)
PH (1) PH12020550214A1 (fr)
TW (1) TWI768129B (fr)
WO (1) WO2019068302A1 (fr)
ZA (1) ZA202002047B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11498977B2 (en) 2016-09-29 2022-11-15 Beijing Hanmi Pharmaceutical Co., Ltd. Heterodimeric immunoglobulin constructs and preparation methods thereof
CA3043652A1 (fr) 2016-11-18 2018-05-24 Beijing Hanmi Pharmaceutical Co., Ltd. Anticorps bispecifique de type structure d'anticorps naturel anti-pd -1/anti-her2 de forme heterodimere et sa preparation
EA202091364A1 (ru) 2017-12-04 2020-10-13 Бейджин Ханми Фармасьютикал Ко., Лтд. Анти-pd-l1/анти-cd47 биспецифическое антитело с подобной природному антителу структурой и в форме гетеродимера и способ его получения
CN109970860A (zh) * 2017-12-27 2019-07-05 信达生物制药(苏州)有限公司 三链抗体、其制备方法及其用途
KR102839330B1 (ko) 2018-01-15 2025-07-30 난징 레전드 바이오테크 씨오., 엘티디. Pd-1에 대한 단일-도메인 항체 및 이의 변이체
WO2019153200A1 (fr) 2018-02-08 2019-08-15 北京韩美药品有限公司 Anticorps bispécifique de type structure d'anticorps naturel anti-pd -1/anti-her2 sous forme hétérodimère et sa préparation
EP3564263A1 (fr) * 2018-05-03 2019-11-06 Universitätsklinikum Hamburg-Eppendorf Protéines de fusion comprenant un vhh spécifique de marqueur de surface cellulair
TW202104260A (zh) 2019-04-05 2021-02-01 美商西建公司 腫瘤選擇性結合ｃｄ４７之抗體之工程
CN113825774B (zh) * 2019-05-17 2024-07-30 南京金斯瑞生物科技有限公司 抗cd47/抗pd-l1多抗原结合蛋白及其使用方法
TWI761869B (zh) * 2019-06-25 2022-04-21 大陸商信達生物製藥（蘇州）有限公司 包含抗cd47/pd-l1雙特異性抗體的製劑及其製備方法和用途
US12358987B2 (en) * 2019-07-08 2025-07-15 Nanjing GenScript Biotech Co., Ltd. Anti-CD47/anti-PD-1 bispecific antibody, preparation method and use thereof
CN115052884B (zh) * 2019-09-27 2026-03-17 北京烁星生物医药科技有限公司 单特异性和多特异性抗体
CN112745392B (zh) * 2019-10-30 2022-07-01 上海洛启生物医药技术有限公司 抗pd-l1/cd47双特异性抗体及其用途
US11702474B2 (en) * 2019-12-17 2023-07-18 Pfizer Inc. Antibodies specific for CD47, PD-L1, and uses thereof
KR102939584B1 (ko) * 2020-02-12 2026-03-16 상하이 에스쿠겐 바이오테크놀로지 컴퍼니 리미티드 인간 cd47-표적화 단일-도메인 항체 및 그 사용
WO2022057939A1 (fr) * 2020-09-21 2022-03-24 I-Mab Biopharma Co., Ltd. Composition pharmaceutique comprenant un anticorps cd47 et un inhibiteur de pd-1/pd-l1
CA3191835A1 (fr) * 2020-09-28 2022-03-31 Jiin-Tarng WANG Anticorps anti-cd47 et methodes d'utilisation
EP4242232A4 (fr) * 2020-11-06 2024-09-11 Bio-Thera Solutions, Ltd. Anticorps bispécifique et son utilisation
WO2022100694A1 (fr) * 2020-11-12 2022-05-19 迈威(上海)生物科技股份有限公司 Anticorps et son procédé de préparation
JP7627349B2 (ja) * 2021-01-08 2025-02-05 北京韓美薬品有限公司 抗ｐｄ－ｌ１／抗ｃｄ４７天然抗体構造様ヘテロダイマー二重特異性抗体及びその製造方法
WO2022177393A1 (fr) * 2021-02-19 2022-08-25 (주)샤페론 Anticorps à domaine unique dirigé contre pd-l1 et son utilisation
KR102836733B1 (ko) * 2021-02-19 2025-07-21 (주)샤페론 Pd-l1 및 cd47에 대한 이중특이적 단일 도메인 항체 및 이의 용도
BR112023016713A2 (pt) * 2021-02-19 2023-10-31 Seoul Nat Univ R&Db Foundation Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo
CA3219221A1 (fr) * 2021-05-07 2022-11-10 Immuneoncia Therapeutics, Inc. Anticorps bispecifique se liant specifiquement a cd47 et pd-l1
CN117858904A (zh) * 2021-06-21 2024-04-09 拜奥卡德联合股份公司 特异性结合cd47和pd-l1的分离的双特异性抗体
CN115702931A (zh) * 2021-08-06 2023-02-17 百奥泰生物制药股份有限公司 抗pd-l1/cd47双特异抗体在治疗疾病中的应用
WO2023051680A1 (fr) * 2021-09-30 2023-04-06 正大天晴药业集团股份有限公司 Anticorps bispécifique pour point de contrôle immunitaire
EP4475886A4 (fr) * 2022-02-09 2026-03-18 Exelixis Inc Agents de liaison multispécifiques et leurs utilisations
KR20230163305A (ko) * 2022-05-19 2023-11-30 (주)샤페론 Pd-l1 및 cd47에 대한 이중특이적 인간화 단일 도메인 항체 및 이의 용도
KR20250044267A (ko) * 2022-07-28 2025-03-31 선전 엔듀어링 바이오테크 리미티드 Peg 기반 항-cd47/항-pd-l1 이중특이적 항체-약물 접합체
WO2024140702A1 (fr) * 2022-12-27 2024-07-04 广东菲鹏制药股份有限公司 Molécule de liaison bispécifique et son utilisation
CN116063526B (zh) * 2022-12-31 2025-03-25 合肥天港免疫药物有限公司 抗pdl1的抗体及其用途
WO2024146539A1 (fr) * 2023-01-04 2024-07-11 Wuxi Biologics (Shanghai) Co., Ltd. Anticorps bispécifiques dirigés contre pd-l1 et cd47, leur procédé de préparation et leur utilisation
WO2025133391A1 (fr) * 2023-12-22 2025-06-26 Numab Therapeutics AG Anticorps multispécifiques ayant une spécificité pour cd47 et pdl1
EP4574844A1 (fr) * 2023-12-22 2025-06-25 Numab Therapeutics AG Anticorps multispécifiques ayant une spécificité pour cd47 et pdl1
WO2025140478A1 (fr) * 2023-12-29 2025-07-03 百奥泰生物制药股份有限公司 Utilisation d'un anticorps bispécifique anti-pd-l1/cd47 en polythérapie

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
EP0479909B1 (fr) 1989-06-29 1996-10-30 Medarex, Inc. Reactifs bispecifiques pour le traitement du sida
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
ATE204902T1 (de) 1990-06-29 2001-09-15 Large Scale Biology Corp Melaninproduktion durch transformierte mikroorganismen
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
WO1993016185A2 (fr) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Proteine de liaison biosynthetique pour marqueur de cancer
EP0656064B1 (fr) 1992-08-17 1997-03-05 Genentech, Inc. Immunoadhesines bispecifiques
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
CA2226962A1 (fr) 1998-02-16 1999-08-16 Marie Sarfati Utilisation d'agents liants a cd47 et ces ligands pour le traitement ou prophylaxie de maladies inflammatoire, autoimmunitaire et allergique et pour le traitement de rejet de greffons
PT1210428E (pt) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
CN1220026C (zh) 2000-08-18 2005-09-21 林德股份公司 用于制造空气分离设备的方法
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
CA2612241C (fr) 2005-07-01 2018-11-06 Medarex, Inc. Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1)
US8168757B2 (en) * 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
PL2342226T3 (pl) 2008-09-26 2017-01-31 Dana-Farber Cancer Institute, Inc. Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania
EP4209510B1 (fr) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
NO2504364T3 (fr) 2009-11-24 2018-01-06
EP4349868A3 (fr) 2010-05-14 2024-08-28 The Board of Trustees of the Leland Stanford Junior University Anticorps monoclonaux humanisés et chimériques contre cd47
EA034778B1 (ru) 2012-02-06 2020-03-19 Инхибркс, Инк. Антитела к cd47 и способы их применения
EP4706769A2 (fr) 2012-12-03 2026-03-11 NovImmune SA Anticorps anti-cd47 et leurs procédés d'utilisation
RU2015122228A (ru) 2012-12-12 2017-01-19 Васкулокс Инк. Терапевтические антитела к CD47
GB201300706D0 (en) 2013-01-15 2013-02-27 Cancer Rec Tech Ltd Antibody
JP2016507555A (ja) 2013-02-06 2016-03-10 インヒブルクス エルピー 血小板非減少性かつ赤血球非減少性ｃｄ４７抗体及びその使用方法
WO2016023001A1 (fr) * 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Agents pd-1 à haute affinité multispécifiques et procédés d'utilisation
WO2016061142A1 (fr) * 2014-10-14 2016-04-21 Novartis Ag Molécules d'anticorps de pd-l1 et leurs utilisations
HK1257309A1 (zh) 2015-09-21 2019-10-18 Erasmus University Medical Center 抗-cd47抗体及使用方法
RU2665790C1 (ru) * 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Моноклональное антитело к pd-l1

Also Published As

Publication number Publication date
EA039662B1 (ru) 2022-02-24
PH12020550214A1 (en) 2021-02-15
NZ763865A (en) 2025-05-30
TW201922781A (zh) 2019-06-16
ZA202002047B (en) 2022-08-31
RU2020115122A3 (fr) 2021-10-29
CA3078413A1 (fr) 2019-04-11
CO2020004199A2 (es) 2020-04-24
MX2020004027A (es) 2020-08-13
CL2020000919A1 (es) 2020-10-16
JOP20200078B1 (ar) 2024-04-17
BR112020006706A2 (pt) 2020-10-06
US11840567B2 (en) 2023-12-12
CN111801352B (zh) 2025-01-14
EP3693390A4 (fr) 2021-11-03
RU2020115122A (ru) 2021-10-29
TWI768129B (zh) 2022-06-21
CN111801352A (zh) 2020-10-20
EP3693390A1 (fr) 2020-08-12
US20200270345A1 (en) 2020-08-27
JP7676474B2 (ja) 2025-05-14
AU2018345458B2 (en) 2025-12-04
AU2018345458A1 (en) 2020-05-14
AU2018345458A2 (en) 2020-05-21
PE20210460A1 (es) 2021-03-08
JP2020535839A (ja) 2020-12-10
EA201791961A1 (ru) 2019-04-30
AR113342A1 (es) 2020-04-22
JOP20200078A1 (ar) 2020-04-30
KR102937863B1 (ko) 2026-03-12
ECSP20024555A (es) 2020-06-30
JP2023130455A (ja) 2023-09-20
MA49599B1 (fr) 2023-05-31
WO2019068302A1 (fr) 2019-04-11
KR20200058542A (ko) 2020-05-27

Similar Documents

Publication Publication Date Title
MA49599B1 (fr) Anticorps spécifiques à cd47 et pd-l1
MX2018007630A (es) Anticuerpos contra la metaloproteinasa de matriz 9.
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
ZA202308021B (en) Anti-ctla4 antibodies and methods of making and using the same
PH12014501931A1 (en) Antibodies to matrix metalloproteinase 9
BR112021017801A2 (pt) Anticorpos biespecíficos anti-vbeta17/anti-cd123
MA39378A1 (fr) Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer
MA35740B1 (fr) Compositions et procédés pour des anticorps ciblant le facteur p
MX2009006891A (es) Anticuerpos cd44.
MA40476B1 (fr) Anticorps et fragments de fixation à l'antigène anti-lag3
EA201101516A1 (ru) Антитела, специфические для кадгерина-17
MA47221A1 (fr) Anticorps monoclonal à pd-l1
MA54969A1 (fr) Anticorps monoclonal se liant spécifiquement à gitr
JOP20210159A1 (ar) أجسام مضادة لـ pmel17 ومترافقات منها
MA44207B1 (fr) Immunoglobulines conjuguées cys80
MA49607A1 (fr) Anticorps monoclonal pour il-5ra
MX2016011177A (es) Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos.
MA43600B2 (fr) Anticorps trispecifique anti il-17a,il-17f et une autre molécule anti-inflammatoire
EA202092672A1 (ru) Антитела против dll3 и их применения
MA41666B1 (fr) Anticorps anti-ox40 et leurs utilisations